CTOs on the Move

Harken Health

www.harkenhealth.com

 
Harken Health is a new kind of health care company that unites relationship-based primary care with a range of competitively priced insurance plan options. Our care approach is rooted in the values of a simpler time when the doctor-patient relationship mattered. Harken Health Care Teams are empowered with the time to listen and build authentic, compassionate, trusting relationships with members. Our model enables us to remove many of the barriers that often get in the way of delivering exceptional care. Strong relationships and a home base for primary care have been shown to improve patient satisfaction and lower overall medical ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Peter Vladimirov
Chief Technology Officer Profile

Similar Companies

Bluegate Corporation

Bluegate Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Houston, TX. To find more information about Bluegate Corporation, please visit www.bluegate.com

LUZ

LUZ is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autonomic Technologies

Autonomic Technologies is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache.

Orthodontic Design and Production

ODP has developed and evolved constantly over the years to reach its present position as one of the world's premier manufactures of orthodontic appliances and accessories. We have been distributing internationally and domestically since we started and

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.